ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Deriv

Opere Ahora

Deriv
Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,011.12
-0.22%
Dow Jones
37,775.38
0.06%
US Dollar vs MXN
17.0713
0.59%
Brent Oil
86.415
-0.66%
Bitcoin
63,617.12
3.81%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) Noticias

RDHL Redhill Biopharma Ltd

0.4152
0.0297 (7.70%)
Fuera de horario
Última actualización: 17:08:11
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Redhill Biopharma Ltd RDHL NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0297 7.70% 0.4152 17:08:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.405 0.39 0.437899 0.4208 0.3855
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/4/202408:23PRNUSRedHill Biopharma Announces Full-Year 2023 Results and..
02/4/202406:00PRNUSRedHill Biopharma Announces $1.25 Million Registered Direct..
11/3/202406:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/3/202406:00PRNUSRedHill Announces New USPTO Patent Covering Talicia® Through..
05/3/202406:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202406:00PRNUSRedHill's Opaganib Selected for Evaluation by BARDA and NIH..
20/2/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202406:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202406:00PRNUSRedHill's Opaganib Protects Against Radiation-Induced Lung..
16/2/202407:54EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
13/2/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202415:10EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202409:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
26/1/202411:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/1/202411:46PRNUSRedHill Biopharma Announces Closing of $8 Million Registered..
26/1/202408:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/1/202408:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/1/202408:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202408:05PRNUSRedHill Biopharma Announces $8 Million Registered Direct..
25/1/202405:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202405:00PRNUSRedHill Announces New USPTO Patent Grant for Talicia® for H...
20/12/202307:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202307:45PRNUSRedHill and U.S. Army Announce Opaganib and RHB-107..
12/12/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202306:00PRNUSRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid..
06/12/202306:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202306:00PRNUSRedHill Announces New, Non-Dilutive External Funding of..
01/12/202315:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202306:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202306:00PRNUSRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market..
16/11/202311:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202307:00PRNUSRedHill Biopharma Announces the Transfer of its Listing to..
26/10/202315:52EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
23/10/202315:06EDGAR2Form F-3/A - Registration statement by foreign private..
16/10/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/10/202307:13EDGAR2Form F-3 - Registration statement by foreign private issuers
10/10/202308:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202306:00PRNUSRedHill and U.S. Army Announce Opaganib's Ebola Virus..
29/9/202307:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202315:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202315:15PRNUSRedHill Biopharma Announces Receipt of Nasdaq Notification..
18/9/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/9/202306:00PRNUSRedHill Announces FDA sNDA Approval for Talicia®
05/9/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202306:00PRNUSRedHill Announces New USPTO Notice of Patent Allowance for..
17/8/202306:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/8/202306:00PRNUSRedHill Biopharma Provides H1/23 Financial Results and..

Su Consulta Reciente

NASDAQ
RDHL
Redhill Biopharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados